InfuSystem Holdings, Inc. (NYSE:INFU) Q3 2024 Results Conference Call November 7, 2024 9:00 AM ET Company Participants Joe Dorame - Managing Partner Rich Dilorio - Chief Executive Officer Barry Steele - Chief Financial Officer Carrie Lachance - President and Chief Operating Officer Conference Call Participants Jim Sidoti - Sidoti & Company Brooks O'Neil - Lake Street Capital Markets Kyle Bauser - B. Riley Securities Matt Hewitt - Craig-Hallum Capital Group Aaron Warwick - Breakout Investors Operator Good da ...

Table of Contents FORM 10-Q Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock, par value $0.0001 per share INFU NYSE American LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2024 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from __ ...

The medical device market, a powerhouse sector, is projected to exceed $600 billion by 2025. This growth is fueled by a combination of factors, including an aging population, rising healthcare costs, and rapid technological advancements powered by advanced artificial intelligence (AI) and biotechnology. These innovations are leading to the development of increasingly sophisticated devices capable of diagnosing and treating a more comprehensive range of conditions with greater precision and effectiveness. Th ...

FORT WORTH, TX, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ: SMTI), a medical technology company focused on improving clinical outcomes and reducing healthcare expenditures in the surgical, chronic wound and skincare markets, and InfuSystem, Inc. ("InfuSystem"), the operational subsidiary of Sanara's joint venture partner InfuSystem Holdings, Inc., announced today the execution of an exclusive U ...

InfuSystem Holdings, Inc. (NYSE:INFU) Q2 2024 Earnings Call Transcript August 8, 2024 9:00 AM ET Company Participants Joe Dorame - Investor Relations Rich Dilorio - Chief Executive Officer Barry Steele - Chief Financial Officer Carrie Lachance - President and Chief Operating Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Matt Hewitt - Craig-Hallum Capital Group Jim Sidoti - Sidoti & Company Operator Good day, and welcome to the InfuSystem Holdings, Inc. Second Quarter 2024 ...

Table of Contents FORM 10-Q Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered Common Stock, par value $0.0001 per share INFU NYSE American LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2024 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ t ...

Rich Dilorio Thank you, Joe, and good morning, everyone. Welcome to InfuSystem's First Quarter 2021 Earnings Call. Thank you all for joining us today. I'll get things started this morning with a quick overview of how we started the year. Barry will go into detail on our financial results for the first quarter, and then Carrie will provide updates on our Biomed Wound Care programs. One of the themes, I'll be developing on today's call is the increasing diversification of our business. Carrie discussed last q ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____ Commission File Number: 001-35020 INFUSYSTEM HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 20-3341405 (State or Other Jurisdiction of Incorporation or O ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K _____________________________________________________________ x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ___________________ Commission File Number: 001-35020 ______________________ ...

Alex Nowak - Craig-Hallum Jim Sidoti - Sidoti & Company Good morning and thanks for joining us today to review InfuSystem's fourth quarter and yearend 2023 financial results ended December 31, 2023. With us today on the call are Rich DiIorio, Chief Executive Officer; Barry Steele, Chief Financial Officer; and Carrie Lachance, President and Chief Operating Officer. After the conclusion of today's prepared remarks, we will open the call for questions. We said at the start of the year that it would be an execu ...